Your browser doesn't support javascript.
A prospective longitudinal study with treated hypertensive patients in Northern Bangladesh (PREDIcT-HTN) to understand uncontrolled hypertension and adverse clinical events: A protocol for 5-years follow-up.
Hossain, Ahmed; Ahsan, Gias Uddin; Hossain, Mohammad Zakir; Hossain, Mohammad Anwar; Sultana, Zeeba Zahra; Arefin, Adittya; Jahan, Shah Mohammad Sarwer; Sutradhar, Probal.
  • Hossain A; Department of Public Health, North South University, Dhaka, Bangladesh.
  • Ahsan GU; Global Health Institute, North South University, Dhaka, Bangladesh.
  • Hossain MZ; Department of Public Health, North South University, Dhaka, Bangladesh.
  • Hossain MA; Hypertension & Research Centre, Rangpur, Bangladesh.
  • Sultana ZZ; TMSS Medical College, Bogra, Bangladesh.
  • Arefin A; Hypertension & Research Centre, Rangpur, Bangladesh.
  • Jahan SMS; Global Health Institute, North South University, Dhaka, Bangladesh.
  • Sutradhar P; Global Health Institute, North South University, Dhaka, Bangladesh.
PLoS One ; 17(5): e0269240, 2022.
Article in English | MEDLINE | ID: covidwho-1933316
ABSTRACT

INTRODUCTION:

Uncontrolled hypertension is the most common cause of major adverse clinical events (MACE), such as myocardial infarction, strokes, and death due to CVDs, in both developed and developing countries. Western-led studies found that treated hypertensive adults with uncontrolled hypertension were more at-risk of all-cause and CVD-specific mortality than normotensives. The PRospEctive longituDInal sTudy of Treated HyperTensive patients of Northern-Bangladesh (PREDIcT-HTN) study principally aims to estimate the incidence of MACE in treated hypertensive patients and identify the determinants of MACE. The secondary objective is to find the prevalence of uncontrolled hypertension in treated hypertensive patients and the associated risk factors. METHODS AND

ANALYSIS:

The treated hypertensive patients were obtained from the Hypertension and Research Center (H&RC), Rangpur, Bangladesh, from January to December 2020. Based on the eligibility criteria, 2643 patients were included to constitute the PREDIcT-HTN cohort. Baseline data was retrieved from the H&RC registry, and five follow-up waves are planned yearly (2021-2025). A questionnaire will be administered at each follow-up visit on hypertension control status, behavioral factors, quality of life, dietary adherence, and high blood pressure compliance-related variables. The participant will be right censored if the patient develops MACE, death due to any cause, loss to follow-up, or at the end of the study. A proportional hazard model will identify the risk factors of MACE. Multinomial logistic regression analyses will be performed to determine the predictors of the hypertension control status by medication and dietary adherence after adjusting confounders. ETHICS AND DISSEMINATION The ethical approval for this study was obtained from the Institutional Review Board, North South University [Ref 2019/OR-NSU/IRB-No.0902]. The participants will provide written consent to participate. The findings will be disseminated through manuscripts in clinical/academic journals and presentations at professional conferences and stakeholder communication.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Hypertension Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0269240

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Cardiovascular Diseases / Hypertension Type of study: Cohort study / Observational study / Prognostic study Limits: Adult / Humans Country/Region as subject: Asia Language: English Journal: PLoS One Journal subject: Science / Medicine Year: 2022 Document Type: Article Affiliation country: Journal.pone.0269240